Ketoconazole and candidiasis: A controlled study

W. T. Hughes, D. L. Bartley, G. G. Patterson, H. Tufenkeji

Research output: Contribution to journalArticlepeer-review

Abstract

A double-blind-controlled study was undertaken to determine the efficacy of ketoconazole in the treatment of candidiasis. The drug was administered orally in the dosage of 200 mg/m2 of body surface per day for two weeks to cancer patients with oral candidiasis. Randomization in a 2:1 ratio provided 36 patients treated with ketoconazole and 20 managed with a placebo. Regression of visible lesions was achieved in 26 (72%) of 36 ketoconazole-treated and four (20%) of 20 untreated patients; eradication of culturable organisms occurred in 12 (36%) of 33 ketoconazole-treated and one (7%) of 14 untreated patients; and resolution of lesions plus eradication of Candida albicans occurred in nine (25%) of 36 ketoconazole-treated and one (5%) of 20 untreated patients. Although the therapeutic efficacy of ketoconazole was demonstrated for oropharyngeal candidiasis, the magnitude of its efficacy was less than that desired.

Original languageEnglish (US)
Pages (from-to)1060-1063
Number of pages4
JournalJournal of Infectious Diseases
Volume147
Issue number6
DOIs
StatePublished - Jan 1 1983

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Ketoconazole and candidiasis: A controlled study'. Together they form a unique fingerprint.

Cite this